Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | Director | July 09, 2026 | July 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PTC THERAPEUTICS, INC.
Report date July 09, 2026 · Filed July 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,813 |
Ending reported balance
After 2026-07-09 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-07-09 · Exercise / conversion · Acquired 10,000 · Balance 31,813 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Row 2 · 2026-07-09 · Sale · Disposed 10,000 · Balance 21,813 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Row 3 · 2026-07-09 · Exercise / conversion · Acquired 5,834 · Balance 27,647 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Row 4 · 2026-07-09 · Sale · Disposed 5,834 · Balance 21,813 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.95 · Expires 2031-06-10 | Direct | 0 |
Reported balance
After 2026-07-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-09 · Exercise / conversion · Disposed 10,000 · Balance 0 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F2: Currently exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.95 · Expires 2031-06-10 | Direct | 0 |
Reported balance
After 2026-07-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-09 · Exercise / conversion · Disposed 5,834 · Balance 0 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F2: Currently exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025.
F2: Currently exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2026 Filed Jul 13, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,834 | $0.00 Strike: $42.95 | $0.00 |
DisclosureSEC source: 0001866044-26-000005 · form4-07132026_050703.xml · derivative · entry 6 Smith Mary L. · CIK 0001866044 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,834 shares Expires 2031-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F2 · derivative.exercise_date: Currently exercisable. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $42.95 | $0.00 |
DisclosureSEC source: 0001866044-26-000005 · form4-07132026_050703.xml · derivative · entry 5 Smith Mary L. · CIK 0001866044 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2031-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F2 · derivative.exercise_date: Currently exercisable. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 5,834 | $90.00 | $525,060.00 |
DisclosureSEC source: 0001866044-26-000005 · form4-07132026_050703.xml · nonDerivative · entry 4 Smith Mary L. · CIK 0001866044 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,813 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 5,834 | $42.95 | $250,570.30 |
DisclosureSEC source: 0001866044-26-000005 · form4-07132026_050703.xml · nonDerivative · entry 3 Smith Mary L. · CIK 0001866044 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,647 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 10,000 | $90.00 | $900,000.00 |
DisclosureSEC source: 0001866044-26-000005 · form4-07132026_050703.xml · nonDerivative · entry 2 Smith Mary L. · CIK 0001866044 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,813 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 10,000 | $42.95 | $429,500.00 |
DisclosureSEC source: 0001866044-26-000005 · form4-07132026_050703.xml · nonDerivative · entry 1 Smith Mary L. · CIK 0001866044 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,813 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:23 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 3,475 | $0.00 Strike: $76.74 | $0.00 |
DisclosureSEC source: 0001866044-26-000003 · form4-01062026_100143.xml · derivative · entry 2 Smith Mary L. · CIK 0001866044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,475 Underlying: Common Stock · 3,475 shares Expires 2036-01-01 F2 · derivative.exercise_date: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:23 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001866044-26-000003 · form4-01062026_100143.xml · nonDerivative · entry 1 Smith Mary L. · CIK 0001866044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,813 F1 · shares: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 8,800 | $0.00 Strike: $46.54 | $0.00 |
DisclosureSEC source: 0001415889-25-001026 · form4-01072025_050124.xml · derivative · entry 2 Smith Mary L. · CIK 0001866044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,800 Underlying: Common Stock · 8,800 shares Expires 2035-01-02 F2 · derivative.exercise_date: This option was granted on January 3, 2025 and vests over one year in twelve equal monthly installments, commencing on February 3, 2025. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001026 · form4-01072025_050124.xml · nonDerivative · entry 1 Smith Mary L. · CIK 0001866044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,813 F1 · shares: Restricted stock units granted on January 3, 2025 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 17, 2025 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 3, 2026. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001415889-24-004098 · form4-02162024_040201.xml · derivative · entry 2 Smith Mary L. · CIK 0001866044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-02-14 F2 · derivative.exercise_date: This option was granted on February 15, 2024 and vests over one year in twelve equal monthly installments, commencing on March 15, 2024. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004098 · form4-02162024_040201.xml · nonDerivative · entry 1 Smith Mary L. · CIK 0001866044 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,813 F1 · shares: Restricted stock units granted on February 15, 2024 that vest over one year, with one-third (1/3) of the shares underlying the RSUs vesting on June 18, 2024 and the remaining two-thirds (2/3) of the original shares underlying the RSUs vesting on February 15, 2025. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001415889-23-000668 · form4-01092023_090106.xml · derivative · entry 2 Smith Mary L. · CIK 0001866044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-01-04 F2 · derivative.exercise_date: This option was granted on January 5, 2023 and vests over one year in twelve equal monthly installments, commencing on February 5, 2023. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-000668 · form4-01092023_090106.xml · nonDerivative · entry 1 Smith Mary L. · CIK 0001866044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,813 F1 · shares: Restricted stock units granted on January 5, 2023 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 6, 2023 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 5, 2024. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 12,000 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001179110-22-000393 · edgar.xml · derivative · entry 2 Smith Mary L. · CIK 0001866044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-01-06 F2 · derivative.exercise_date: This option was granted on January 7, 2022 and vests over one year in twelve equal monthly installments, commencing on February 7, 2022. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-000393 · edgar.xml · nonDerivative · entry 1 Smith Mary L. · CIK 0001866044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,813 F1 · shares: Restricted stock units granted on January 7, 2022 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 8, 2022 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 7, 2023. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 21:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 5,834 | $0.00 Strike: $42.95 | $0.00 |
DisclosureSEC source: 0001179110-21-006723 · edgar.xml · derivative · entry 4 Smith Mary L. · CIK 0001866044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,834 Underlying: Common Stock · 5,834 shares Expires 2031-06-10 F4 · derivative.exercise_date: This option was granted on June 11, 2021 and vests over seven approximately equal monthly installments, commencing on July 6, 2021. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 21:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $42.95 | $0.00 |
DisclosureSEC source: 0001179110-21-006723 · edgar.xml · derivative · entry 3 Smith Mary L. · CIK 0001866044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-10 F3 · derivative.exercise_date: This option was granted on June 11, 2021 and vests over thirty-six approximately equal monthly installments, commencing on July 8, 2021. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 21:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 963 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-006723 · edgar.xml · nonDerivative · entry 2 Smith Mary L. · CIK 0001866044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,613 F2 · shares: Restricted stock units granted on June 11, 2021 that vest on January 6, 2022. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 21:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 1,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-006723 · edgar.xml · nonDerivative · entry 1 Smith Mary L. · CIK 0001866044 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650 F1 · shares: Restricted stock units granted on June 11, 2021 that vest in three equal installments over three years, commencing on June 8, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.